Workflow
迈瑞医疗
icon
Search documents
大洗牌!流式细胞仪2025年度中标盘点
仪器信息网· 2026-03-04 07:13
摘要: 2025年中国流式细胞仪市场迎来"分水岭"。在地缘政治不确定性成为常态的背景下,"深度本土化"已从企业战略选项变为生存刚需。 特别提示 微信机制调整,点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标,否则很可能无法看到我们的推送。 2025年是中国流式细胞仪市场的一个"分水岭",年初美国高参数流式细胞仪出口禁令的发布及中美关税战,成为搅动全年市场格局的关键变 量。透过公开中标数据,我们看到的不仅是贝克曼库尔特在中标数量上反超BD,在中标金额上与BD的差距大幅缩减的表象,更是一场由地缘 政治、本土化战略与下沉市场需求共同驱动的行业洗牌。 近日,仪器信息网对2025年流式细胞仪公开中标数据进行了整理和分析,统计到的合计中标金641297934元,合计中标数量486台。BD再 次蝉联2025年流式细胞仪中标金额TOP1,贝克曼库尔特、Cy tek分列第二、第三,剩余中标金额前十厂商依次为安捷伦、SONY、赛默飞、 Standard BioTool s 、 层 浪 生 物 、 唯 公 、 迈 瑞 。 市 场 头 部 集 中 度 依 然 显 著 , 中 标 金 额 前 三 厂 商 合 计 占 比 超 ...
美敦力与GE医疗合作再升级!助力医院平台化
思宇MedTech· 2026-03-04 05:57
2026年3月3日,医疗器械巨头美敦力(Medtronic)宣布,与GE医疗GE HealthCare续签合作,并大幅扩展双方的全球战略联盟。这一合作建立在双方超过30年的技 术协作基础之上,新的协议将持续多年,重点围绕 患者监护(Patient Monitoring)技术与医院平台系统的深度整合 展开。 根据双方披露的信息,本次合作的核心在于将美敦力的一系列临床监护参数与技术,进一步整合进入GE医疗的Patient Care Solutions平台。涉及的技术包括 Nellcor 脉搏血氧监测、Microstream呼气末二氧化碳监测(capnography)、INVOS区域氧饱和度监测以及BIS脑电深度监测 等。这些监护参数将与GE的监护设备和信息系 统协同运行,并覆盖包括麻醉、重症监护、母婴护理等多个临床场景。 同时,双方还计划将合作延伸至 新一代无线可穿戴监护技术,以及视频喉镜等麻醉气道管理设备 ,以推动医院监护系统向更加连续化、数字化的方向演进。 从更长周期观察,这类合作背后反映了医疗设备行业一个逐渐清晰的趋势: 从单一设备竞争,转向平台生态与临床数据能力的竞争。 # 监护技术:从"设备参数"走向" ...
中东紧张局势升级,对中国医疗企业出海影响几何?
第一财经· 2026-03-04 03:10
作者 | 第一财经 钱童心 美国和以色列对伊朗发起军事行动以来,中东地区紧张局势升级,对于在中东有业务布局的中国医疗 企业会产生哪些影响引发关注。 第一财经记者3月3日从多位医疗器械设备行业人士方面了解情况,大部分厂商表示,目前战局的影 响主要在于物流方面。由于中国医疗厂商在中东的业务起步相对较晚,占比量不大,产生的影响也较 为有限。 一位国内医疗设备厂商负责人对第一财经记者表示,尽管很多中国企业近年来出海的需求迫切,但大 部分公司仍在观望,或者是刚刚开始布局。目前在中东业务量相对较大的还是一些大型的上市公司。 以医疗设备而言,国内两大巨头企业联影和迈瑞都在中东开展业务。联影医疗尚未对中东战局影响发 表公开回应,但知情人士对第一财经记者表示:"联影在中东的业务占比比较低,基本没有影响。" 2026.03. 04 本文字数:1536,阅读时长大约3分钟 另一位国内医疗器械及注射药品厂商方面人士也向第一财经记者透露,目前的局势尚未对该公司在中 东的业务产生影响,本身的业务量也不大。 一位最近从迪拜回国的专家对第一财经记者表示,中国医疗企业在中东未来发展的另一个极具潜力的 方向是人工智能,可能会带来较大的业务机会。 ...
迈瑞医疗-实地调研要点:对中国设备复苏信心增强,而体外诊断业务面临不确定性
2026-03-03 03:13
2 March 2026 | 4:27PM CST Equity Research Mindray (300760.SZ): Key trip takeaways: Increased confidence in China equipment rebound while IVD faces uncertainties We visited Mindray on Feb 27, 2026. Below are our key takeaways. Domestic medical equipment market environment and competitive landscape: The company believes that the market concentration of ultrasound equipment is already high, which may limit opportunities for new entrants. The company expects its domestic growth rate to be largely in line with t ...
中银晨会聚焦-20260303
| 3 月金股组合 | | | --- | --- | | 股票代码 | 股票名称 | | 0119.HK | 保利置业集团 | | 000099.SZ | 中信海直 | | 601872.SH | 招商轮船 | | 600352.SH | 浙江龙盛 | | 002409.SZ | 雅克科技 | | 002709.SZ | 天赐材料 | | 300760.SZ | 迈瑞医疗 | | 605338.SH | 巴比食品 | | 1579.HK | 颐海国际 | | 601888.SH | 中国中免 | | 689009.SH | 九号公司-WD | | 688630.SH | 芯碁微装 | | 市场指数 | | | | --- | --- | --- | | 指数名称 | 收盘价 | 涨跌% | | 上证综指 | 4182.59 | 0.47 | | 深证成指 | 14465.79 | (0.20) | | 沪深 300 | 4728.67 | 0.38 | | 中小 100 | 8847.90 | 0.14 | | 创业板指 | 3294.16 | (0.49) | 证券研究报告——晨会聚焦 2026 年 3 ...
医疗器械行业ESG白皮书
荣续智库· 2026-03-02 09:20
Investment Rating - The report does not explicitly provide an investment rating for the medical device industry. Core Insights - The medical device industry is experiencing continuous growth globally, driven by advancements in technology, materials, and concepts, which enhance product functionality and precision [6][32]. - The industry plays a crucial role in improving healthcare services and resource allocation, significantly impacting accessibility and equity in medical care [6][32]. - The report emphasizes the importance of ESG (Environmental, Social, and Governance) principles, highlighting that adherence to these standards can enhance corporate image and drive sustainable development within the industry [7][56]. Summary by Sections Chapter 1: Overview of the Medical Device Industry - The upstream segment includes raw material supply and technology research and development, which are foundational for medical device production [19][20]. - The midstream segment focuses on product design, manufacturing, marketing, and distribution, emphasizing the need for compliance with regulatory standards [20][24]. - The downstream segment pertains to the application of medical devices in various healthcare settings, where performance, safety, and user experience are critical [29][30]. Chapter 2: ESG Development in the Medical Device Industry - The report discusses the current state of ESG information disclosure, noting that the healthcare sector has a disclosure rate of 39%, slightly below the average [56][57]. - It highlights the need for improved transparency and accountability in ESG reporting, as many companies focus on achievements while neglecting potential risks [58]. - The report outlines various domestic and international policies that guide the medical device industry towards sustainable practices, including regulations on waste management and product safety [59][62]. Chapter 3: ESG Practice Cases in the Medical Device Industry - The report presents case studies of leading companies in the medical device sector, showcasing their ESG practices and contributions to sustainable development [7][56]. - It emphasizes the importance of integrating ESG principles into corporate strategies to enhance competitiveness and address societal expectations [58][59].
中银晨会聚焦-20260302-20260302
Core Insights - The report emphasizes the potential for investment opportunities in commodities driven by geopolitical tensions, particularly in the Middle East, which may lead to rising prices for oil and precious metals in 2026 [2][5][6] - The A-share market is expected to experience short-term volatility due to geopolitical factors, but will likely refocus on domestic fundamentals and policy expectations in the medium term [3][15] - The report highlights a significant investment in AI applications by major domestic internet companies, indicating a competitive landscape focused on user habit formation and commercial viability [9][12] Market Overview - The report lists a "March Gold Stock Portfolio" featuring companies such as Poly Real Estate Group, CITIC Hanzhong, and Mindray Medical, indicating a focus on sectors like real estate, transportation, and healthcare [1][7] - The A-share market indices showed mixed performance, with the Shanghai Composite Index closing at 4162.88, up 0.39%, while the Shenzhen Component Index fell by 0.06% [1] - The report notes that the steel industry performed well, with a 3.37% increase, while sectors like construction materials and telecommunications saw declines [1] Commodity Insights - The report anticipates that geopolitical events will significantly impact oil and certain petrochemical product prices, with a focus on the implications of the closure of the Strait of Hormuz [5][29] - It is projected that Brent crude oil prices could exceed $80 per barrel due to potential supply disruptions from Iran, with historical comparisons to the 2022 Ukraine conflict [5][29] - The chemical industry is advised to focus on low-valuation leading companies and sectors benefiting from price increases under the "anti-involution" policy [28][33] AI Industry Developments - Major domestic internet companies invested over 4.5 billion yuan in promoting AI applications during the Spring Festival, marking a shift towards practical applications and user engagement [9][12] - The report highlights the rapid evolution of domestic AI models, with significant advancements in performance and market application, indicating a dual development path towards general models and vertical industry applications [10][12] - Concerns about AI replacing human jobs are noted, but the report emphasizes that current AI capabilities are more about enhancement rather than replacement [11][12] Investment Recommendations - The report suggests focusing on companies in the AI sector and those involved in the development of general models and industry-specific AI agents, such as MINIMAX-WP and iFLYTEK [13][12] - It also recommends monitoring traditional chemical leaders that are adapting to new materials and benefiting from improving industry conditions [33]
中银证券研究部2026年3月金股
策略研究 | 证券研究报告 — 总量点评 2026 年 3 月 1 日 3 月金股组合 中银证券研究部 2026 年 3 月金股 3 月金股组合 中银国际证券股份有限公司 具备证券投资咨询业务资格 策略研究 证券分析师:王君 (8610)66229061 jun.wang@bocichina.com 证券投资咨询业务证书编号:S1300519060003 证券分析师:徐沛东 (8621)20328702 peidong.xu@bocichina.com 证券投资咨询业务证书编号:S1300518020001 策略观点:A 股短期波动中期聚焦国内主线,资源品行情正当时。美以 军事打击伊朗对于全球市场及资产价格的影响取决于行动的目标及持续 性。金价上行有望得到进一步支撑。无论是当下的中东局势还是特朗普 关税政策的反复都为短期市场增加了较高的不确定性因素。而这种不确 定性下的避险情绪将为短期贵金属价格形成有力支撑。目前来看,对于 A 股的影响更多集中在风险偏好层面,中期来看,A 股市场将会回归国内 基本面及政策预期。国内两会即将开幕,A 股短期冲击幅度或小于海外, 节后复工情况、两会前后宏观政策的释放是国内投资者关 ...
医药生物行业跨市场周报(20260301):坚定看好医药板块回暖,重申投资临床价值三段论-20260301
EBSCN· 2026-03-01 05:06
2026 年 3 月 1 日 行情回顾:上周 A 股医药生物(申万,下同)指数上涨 0.50%,跑输沪深 300 指数 0.58pp,跑输创业板综指 1.82pp,在 31 个子行业中排名第 25。港股恒生 医疗健康指数上周收跌 6.07%,跑输恒生国企指数 4.96pp。 研发进展:上周,康哲药业的 CMS-D008 注射液、康辰药业的 KC1036 片的临 床申请新进承办;海思科的 HSK46575 片、百利天恒的注射用伦康依隆妥单抗 和注射用 BL-M11D1 的 IND 申请新进承办;恒瑞医药的 SHR-1905 注射液以及 SHR-1819 注射液申请临床。 上周,诺诚健华的 ICP-538 以及华润双鹤的 DC6001 正在进行一期临床;复宏 汉霖的 HLX43 和天境生物的普那利单抗进行二期临床;石药集团的 SYH2053 和 SYS6010 进行三期临床;禾元生物的重组人白蛋白(水稻)进行四期临床。 本周观点:坚定看好医药板块回暖,重申投资临床价值三段论 从临床价值三段论看投资主线:1)"0→1"技术突破:创新药领域,高端前沿 创新靶点,正在肿瘤、减重、自免等领域重塑药企研发格局;创新器械领域 ...
成明和捐赠1亿元,上海交大两日内收到三笔亿元级捐赠
Xin Lang Cai Jing· 2026-02-28 03:21
智通财经记者注意到,这已是上海交大两日内的第三笔大额捐赠。 2月26日上午,"全季人文发展基金"捐赠签约暨季琦校董聘任仪式举行。华住集团创始人、交大工程力 学系1989届本科校友、机械工程系1992届硕士校友季琦学长向母校捐资1亿元人民币,支持学校各项事 业发展。 同日下午,"求实创新发展教育基金"捐赠签约仪式举行。东方财富信息股份有限公司董事长、交大1993 届材料工程系本科校友、学校校董其实捐赠东方财富股票2000万股(市值约4.5亿元)以支持母校教育 事业发展,聚焦人才培养及科技创新。 2026年,上海交大将于4月8日上午举行"庆祝上海交通大学建校130周年大会",每年这个日子前后,也 是交大庆祝校庆的日子。智通财经记者注意到,上海交大官网特别开出专题"聚爱思源 同心致远",集 中呈现自2025年4月10日至今的每一份捐赠记录。记者统计发现,一年不到的时间,上海交大已收到超 50场捐赠,包括捐资、捐物等,其中,单次达亿元级的捐赠不下5场。 两日内,上海交大接连收到三笔大额捐赠,数额共达约6.5亿元。 2月27日下午,"上海交通大学佳和基金"捐赠仪式举行,上海交通大学校董、迈瑞医疗联合创始人、 1985届 ...